AviadoBio expands presence at Canary Wharf

Published: 18-Apr-2024

The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

AviadoBio, a gene therapy company specialising in the development of medicines for neurodegenerative disorders, is expanding its presence at Canary Wharf.

In addition to its space at Kadans Science Partner’s London Innovation Centre at 20 Water Street, AviadoBio will also now lease 11,000 sqft of laboratory and office space on level six of 20 Water Street. 

This leasing further expands the growing life sciences cluster being developed at Canary Wharf by Kadans and Canary Wharf Group (CWG).

This expansion will allow AviadoBio to bring its 60-strong team together under one roof, while providing space for the life science company to continue to grow, as well as build on its ambitions of nurturing breakthrough discoveries.

20 Water Street forms part of the growing life sciences community at Canary Wharf, which also includes Kadans’ and CWG’s development of an 823,000 sqft GIA commercial health and life sciences building on the 3.3-hectare North Quay site, which is expected to be complete in 2027.

Lisa Deschamps, CEO of AviadoBio, said: “Since moving into our space at the London Innovation Centre we have been able to continue important work developing our programmes and pipeline, while being surrounded by others within the life science community. Having seen what Canary Wharf offers growing life sciences companies, we felt it was the right time for us to consolidate our UK lab and office space into one central hub here in Canary Wharf. It provides everything we need to be able to continue working on projects that will transform the lives of patients living with neurodegenerative disorders and allows us room to grow as we expand our business.”


You may also like